Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eisai Co.’s breakthrough Alzheimer’s drug Leqembi was cleared for use in the European Union, after the medicine was approved in the US and Japan. The European Commission approved the drug to treat ...

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected ...

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of developing symptoms was cut in half, according to a new srudy.

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...

A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling. The European Medicines Agency ...

Some neurologists and a consumer watchdog worry that an Eli Lilly–affiliated direct-to-consumer telehealth platform for Alzheimer’s could lead to misdiagnosis or unnecessary treatment.

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

Manufacturers of Alzheimer’s disease drugs have identified blood tests as a way to accelerate diagnosis and treatment.

The new offering is focused on shortening the time it takes to reach an Alzheimer’s diagnosis and therefore begin treatment, according to Lilly, citing data showing that the average wait time to ...

The risk for amyloid-related imaging abnormalities in early-stage Alzheimer’s disease is primarily driven by the ...